FineDuo—a low profile, multifunctional, dual-lumen microcatheter—now has the CE mark. The device has been developed for use during percutaneous transluminal coronary angioplasty for guidewire support for crossing side branch and exchange of guidewires. According to a press release, it provides provide robust support and easy access to complex coronary vasculature.
BTG has launched the βETA Radiation Safety Programme, a new initiative designed to reduce the risk of radiation exposure when performing selective internal radiation therapy (SIRT) with 90Y microspheres. Developed in collaboration with global experts, including Jacob Kamen of the Mount Sinai Medical Center, the βETA Radiation Safety Programme analyses current practise and exposure risk, and provides recommendations to improve safety for healthcare professionals and patients.
The SIRT Users’ Network of professionals who treat liver cancer is to extend across the UK, Belgium, Spain and Italy
Royal Philips has announced the unveiling of its latest innovation in interventional oncology at the Cardiovascular and Interventional Radiological Society of Europe annual meeting (CIRSE 2016, 10-14 September, Barcelona, Spain).
Dfine’s products are directed to vertebral augmentation (kyphoplasty and vertebroplasty), as well as targeted radiofrequency ablation of metastatic spinal tumours and these product lines have 510(k) clearance and CE marking.
Bruno Sangro, director of the Liver Unit and co-director, of the HPB Oncology Area, Clinca Universidad de Navarra, Pamplona, Spain, delivered the European Conference on Interventional Oncology (ECIO) Honorary Lecture on the topic “Intra-arterial treatment of hepatocellular carcinoma (HCC) at the dawn of systemic therapy”. ECIO took place 17–20 April, in Dublin, Ireland.
The role of embolization in musculoskeletal pain management, treatment of haemorrhoidal bleeding and lymphatic interventions were among the highlights of a special session titled The Embolization Vanguard at the Global Embolization Symposium and Technologies (GEST 2016 US, 5–8 May, New York, USA) meeting.
The Netherlands presidency of the European Council and representatives of the European Parliament have reached a political agreement on two draft regulations for medical devices. The new regulations are aimed at ensuring that medical devices and in vitro diagnostic medical devices are safe while allowing patients to benefit of innovative health care solutions in a timely manner. However, the agreement is subject to the approval by the Council’s Permanent Representatives Committee and of the Parliament’s ENVI committee.
Merit has announced that it has signed a distribution deal with Piolax Medical Devices of Yokohama, Japan for a product known in Japan as the Labyrinth Noah micro guidewire.
We know from the randomised controlled trials from the UK, Denmark and West Australia that screening elderly men for abdominal aortic aneurysm with ultrasound saves lives and is cost-effective. According to the latest results from the British MASS trial, screening decreases all-cause mortality by 3% (95% confidence intervals, 1–5%) in the overall screened population—an extraordinary result. These results are the rationale behind the establishment of national screening programmes for 65-year-old men in England and Sweden, and the US Medicare and the Society for Vascular Surgery recommendation of aneurysm screening of men and smoking women.
As our understanding of dissection grows, the fate of the false lumen through the progression of disease is becoming a more important variable that predicts outcome, writes Tara Mastracci. If stenting is performed in the acute or subacute phase, in a majority of patients, the false lumen will thrombose to the level of the stent, or beyond, promoting aortic remodelling and thus decreasing the need for further intervention. However, in that subset of patients in whom the false lumen remains perfused or pressurised, aneurysmal degeneration occurs and the risk of rupture and death remains a persistent threat.
A recent comparison of in-hospital mortality following rupture of an abdominal aortic aneurysm in England and the USA suggests that too few patients in England are being selected for aneurysm repair, too few are treated in high-volume centres and too few are offered endovascular (EVAR) versus open repair, writes Michael Sweeting.
Prakash Krishnan, Mount Sinai Medical Center, New York, USA, presented the second interim analysis of 12-month data from the ILLUMENATE Global Study at the New Cardiovascular Horizons (NCVH) annual conference (1–3 June, New Orleans, USA). The ILLUMENATE Global Study is a prospective, multicentre, single-arm study designed to assess the clinical performance of the Stellarex drug-coated balloon (DCB) in the superficial femoral and popliteal arteries.
Medtronic and the University of Texas Health Science Center at Houston (UTHealth) have announced the first patient enrolled in a clinical study assessing the Medtronic Valiant Evo thoracic stent graft system for the minimally invasive repair of descending thoracic aortic aneurysms (TAA). The international, multicentre, prospective study will include 100 patients in the USA and Europe. The news was reported at the 2016 Vascular Annual Meeting of the Society for Vascular Surgery (8–11 June, National Harbor, USA).
VentureMed has announced receipt of US Food and Drug Administration (FDA) 510(k) clearance for the Flex scoring catheter, an endovascular device that precisely and dynamically scores any length of atherosclerotic lesion as it passes through the femoral-popliteal anatomy. Flex received European CE mark approval in 2015.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos